C-met affects gemcitabine resistance during carcinogenesis in a mouse model of pancreatic cancer

Kozo Noguchi, Masamitsu Konno, Hidetoshi Eguchi, Koichi Kawamoto, Ryouta Mukai, Naohiro Nishida, Jun Koseki, Hiroshi Wada, Hirofumi Akita, Taroh Satoh, Shigeru Marubashi, Hiroaki Nagano, Yuichiro Doki, Masaki Mori, Hideshi Ishii

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Pancreatic adenocarcinoma is thought to develop from histologically identifiable intraductal lesions known as pancreatic intraepithelial neoplasias (PanINs), which exhibit similar morphological and genetic features to pancreatic ductal adenocarcinoma (PDAC). Therefore, a better understanding of the biological features underlying the progression of PanIN is essential to development more effective therapeutic interventions for PDAC. In recent years, numerous studies have reported that MET proto-oncogene receptor tyrosine kinase (c-MET) is a potential marker of pancreatic cancer stem cells (CSCs). CSCs have been revealed to initiate and propagate tumors in vitro and in vivo, and are associated with a chemoresistant phenotype. However, in vivo models using a xenograft approach are limited. In the present study, the morphological phenotype, molecular alteration and biological behavior of neoplasia in Pdx-1Cre/+, KrasLSL -G12D/+ and Metflox/flox and wild-type mice was analyzed. The results demonstrated that while oncogenic KrasLSL -G12D/+increased PanIN initiation and significantly decreased survival rate compared with wild-type mice, no additive effect of c-Met receptor signaling on PanIN progression or prognosis was observed. Following gemcitabine administration, c-Met inhibition in KrasLSL -G12D/+ mice significantly decreased the total surface area of PanIN lesions and the number of anti-proliferation marker protein Ki-67 positive cells occupying PanIN lesions compared with Met+/+ mice. In conclusion, complete inhibition of the c-Met signaling pathway with chemotherapy may be useful for the treatment of pancreatic cancer.

Original languageEnglish
Pages (from-to)1892-1898
Number of pages7
JournalOncology Letters
Volume16
Issue number2
DOIs
Publication statusPublished - Aug 2018

Fingerprint

gemcitabine
Pancreatic Neoplasms
Carcinogenesis
Adenocarcinoma
Neoplastic Stem Cells
Proto-Oncogene Proteins c-met
Phenotype
Neoplasms
Proto-Oncogenes
Heterografts
Drug Therapy
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Noguchi, K., Konno, M., Eguchi, H., Kawamoto, K., Mukai, R., Nishida, N., ... Ishii, H. (2018). C-met affects gemcitabine resistance during carcinogenesis in a mouse model of pancreatic cancer. Oncology Letters, 16(2), 1892-1898. https://doi.org/10.3892/ol.2018.8793

C-met affects gemcitabine resistance during carcinogenesis in a mouse model of pancreatic cancer. / Noguchi, Kozo; Konno, Masamitsu; Eguchi, Hidetoshi; Kawamoto, Koichi; Mukai, Ryouta; Nishida, Naohiro; Koseki, Jun; Wada, Hiroshi; Akita, Hirofumi; Satoh, Taroh; Marubashi, Shigeru; Nagano, Hiroaki; Doki, Yuichiro; Mori, Masaki; Ishii, Hideshi.

In: Oncology Letters, Vol. 16, No. 2, 08.2018, p. 1892-1898.

Research output: Contribution to journalArticle

Noguchi, K, Konno, M, Eguchi, H, Kawamoto, K, Mukai, R, Nishida, N, Koseki, J, Wada, H, Akita, H, Satoh, T, Marubashi, S, Nagano, H, Doki, Y, Mori, M & Ishii, H 2018, 'C-met affects gemcitabine resistance during carcinogenesis in a mouse model of pancreatic cancer', Oncology Letters, vol. 16, no. 2, pp. 1892-1898. https://doi.org/10.3892/ol.2018.8793
Noguchi, Kozo ; Konno, Masamitsu ; Eguchi, Hidetoshi ; Kawamoto, Koichi ; Mukai, Ryouta ; Nishida, Naohiro ; Koseki, Jun ; Wada, Hiroshi ; Akita, Hirofumi ; Satoh, Taroh ; Marubashi, Shigeru ; Nagano, Hiroaki ; Doki, Yuichiro ; Mori, Masaki ; Ishii, Hideshi. / C-met affects gemcitabine resistance during carcinogenesis in a mouse model of pancreatic cancer. In: Oncology Letters. 2018 ; Vol. 16, No. 2. pp. 1892-1898.
@article{ebd70d9bb2324c259f64175790ba0e8d,
title = "C-met affects gemcitabine resistance during carcinogenesis in a mouse model of pancreatic cancer",
abstract = "Pancreatic adenocarcinoma is thought to develop from histologically identifiable intraductal lesions known as pancreatic intraepithelial neoplasias (PanINs), which exhibit similar morphological and genetic features to pancreatic ductal adenocarcinoma (PDAC). Therefore, a better understanding of the biological features underlying the progression of PanIN is essential to development more effective therapeutic interventions for PDAC. In recent years, numerous studies have reported that MET proto-oncogene receptor tyrosine kinase (c-MET) is a potential marker of pancreatic cancer stem cells (CSCs). CSCs have been revealed to initiate and propagate tumors in vitro and in vivo, and are associated with a chemoresistant phenotype. However, in vivo models using a xenograft approach are limited. In the present study, the morphological phenotype, molecular alteration and biological behavior of neoplasia in Pdx-1Cre/+, KrasLSL -G12D/+ and Metflox/flox and wild-type mice was analyzed. The results demonstrated that while oncogenic KrasLSL -G12D/+increased PanIN initiation and significantly decreased survival rate compared with wild-type mice, no additive effect of c-Met receptor signaling on PanIN progression or prognosis was observed. Following gemcitabine administration, c-Met inhibition in KrasLSL -G12D/+ mice significantly decreased the total surface area of PanIN lesions and the number of anti-proliferation marker protein Ki-67 positive cells occupying PanIN lesions compared with Met+/+ mice. In conclusion, complete inhibition of the c-Met signaling pathway with chemotherapy may be useful for the treatment of pancreatic cancer.",
author = "Kozo Noguchi and Masamitsu Konno and Hidetoshi Eguchi and Koichi Kawamoto and Ryouta Mukai and Naohiro Nishida and Jun Koseki and Hiroshi Wada and Hirofumi Akita and Taroh Satoh and Shigeru Marubashi and Hiroaki Nagano and Yuichiro Doki and Masaki Mori and Hideshi Ishii",
year = "2018",
month = "8",
doi = "10.3892/ol.2018.8793",
language = "English",
volume = "16",
pages = "1892--1898",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "2",

}

TY - JOUR

T1 - C-met affects gemcitabine resistance during carcinogenesis in a mouse model of pancreatic cancer

AU - Noguchi, Kozo

AU - Konno, Masamitsu

AU - Eguchi, Hidetoshi

AU - Kawamoto, Koichi

AU - Mukai, Ryouta

AU - Nishida, Naohiro

AU - Koseki, Jun

AU - Wada, Hiroshi

AU - Akita, Hirofumi

AU - Satoh, Taroh

AU - Marubashi, Shigeru

AU - Nagano, Hiroaki

AU - Doki, Yuichiro

AU - Mori, Masaki

AU - Ishii, Hideshi

PY - 2018/8

Y1 - 2018/8

N2 - Pancreatic adenocarcinoma is thought to develop from histologically identifiable intraductal lesions known as pancreatic intraepithelial neoplasias (PanINs), which exhibit similar morphological and genetic features to pancreatic ductal adenocarcinoma (PDAC). Therefore, a better understanding of the biological features underlying the progression of PanIN is essential to development more effective therapeutic interventions for PDAC. In recent years, numerous studies have reported that MET proto-oncogene receptor tyrosine kinase (c-MET) is a potential marker of pancreatic cancer stem cells (CSCs). CSCs have been revealed to initiate and propagate tumors in vitro and in vivo, and are associated with a chemoresistant phenotype. However, in vivo models using a xenograft approach are limited. In the present study, the morphological phenotype, molecular alteration and biological behavior of neoplasia in Pdx-1Cre/+, KrasLSL -G12D/+ and Metflox/flox and wild-type mice was analyzed. The results demonstrated that while oncogenic KrasLSL -G12D/+increased PanIN initiation and significantly decreased survival rate compared with wild-type mice, no additive effect of c-Met receptor signaling on PanIN progression or prognosis was observed. Following gemcitabine administration, c-Met inhibition in KrasLSL -G12D/+ mice significantly decreased the total surface area of PanIN lesions and the number of anti-proliferation marker protein Ki-67 positive cells occupying PanIN lesions compared with Met+/+ mice. In conclusion, complete inhibition of the c-Met signaling pathway with chemotherapy may be useful for the treatment of pancreatic cancer.

AB - Pancreatic adenocarcinoma is thought to develop from histologically identifiable intraductal lesions known as pancreatic intraepithelial neoplasias (PanINs), which exhibit similar morphological and genetic features to pancreatic ductal adenocarcinoma (PDAC). Therefore, a better understanding of the biological features underlying the progression of PanIN is essential to development more effective therapeutic interventions for PDAC. In recent years, numerous studies have reported that MET proto-oncogene receptor tyrosine kinase (c-MET) is a potential marker of pancreatic cancer stem cells (CSCs). CSCs have been revealed to initiate and propagate tumors in vitro and in vivo, and are associated with a chemoresistant phenotype. However, in vivo models using a xenograft approach are limited. In the present study, the morphological phenotype, molecular alteration and biological behavior of neoplasia in Pdx-1Cre/+, KrasLSL -G12D/+ and Metflox/flox and wild-type mice was analyzed. The results demonstrated that while oncogenic KrasLSL -G12D/+increased PanIN initiation and significantly decreased survival rate compared with wild-type mice, no additive effect of c-Met receptor signaling on PanIN progression or prognosis was observed. Following gemcitabine administration, c-Met inhibition in KrasLSL -G12D/+ mice significantly decreased the total surface area of PanIN lesions and the number of anti-proliferation marker protein Ki-67 positive cells occupying PanIN lesions compared with Met+/+ mice. In conclusion, complete inhibition of the c-Met signaling pathway with chemotherapy may be useful for the treatment of pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=85049455073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049455073&partnerID=8YFLogxK

U2 - 10.3892/ol.2018.8793

DO - 10.3892/ol.2018.8793

M3 - Article

AN - SCOPUS:85049455073

VL - 16

SP - 1892

EP - 1898

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 2

ER -